Table 1

Study sample characteristics

Variable	Patient no.														Mean± SD
Variable	1		2		3		4		5		6		7		Mean± SD
Age (years)	56		21		46		16		23		31		52		36±16
Autosomal Dominant RP	Y				Y		Y		Y		Y		Y
Length of VPA treatment (months)	2		2		4		4		4		6		5		4±1
Mean dose of VPA (mg/day)	750		750		500		500		500		500		750		643±133
Eye	OD	OS	OD	OS	OD	OS	OD	OS	OD	OS	OD	OS	OD	OS	OD	OS
Visual Field at baseline (mm²) (isopter V4e)	192	165	148	107	38	201	562	558	504	–	278	450	442	434	309±197	319±184
Visual Field at follow-up (mm²)	210	187	165	118	96	200	586	594	452	–	517	575	448	385	353±192	343±207
Visual Acuity at baseline (logMAR)	1	1	0.544	0.301	0.176	0.301	0	0	0	0.097	1.301	0.097	0.176	0.301	0.456±0.515	0.300±0.332
Visual acuity at follow-up (logMAR)	0.176	0.301	0.544	0.176	0.097	0.301	0	0	0	0.097	1	0.097	0	0.097	0.260±0.380	0.153±0.113

LogMAR, logarithm of the minimum angle of resolution; OD, right eye; OS, left eye; RP, retinitis pigmentosa; VPA, valproic acid.